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Abstract Urolcinase-type lasminogen activator (UPA) mRNA is induced in macrophages by the lineage specific growth factor CSF-1. Upon removal 
of CSF-1 from bone marrow-derived macrophages (BMM), UPA mRNA decayed with a half-life of 2 h. If RNA synthesis inhibitors actinomycin 
D, 5,6-dichloro-1-/Lribofuranosyl benzimidazole (DRB) or cz-amanitin were added at the time as CSF-1 removal, the UPA message was stabilised. 
This was not a general effect on CSF-1 responsive mRNAs, as c-myc mRNA decayed with normal kinetics in the presence of inhibitors. The 
requirement for ongoing RNA synthesis for the degradation ofUPA mRNA in BMM suggests hat a component of the degradative pathway may 
be induced following removal of CSF-1. 
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1. Introduction 
Regulated mRNA decay is emerging as an important process 
in determining the levels of gene expression. A variety of mech- 
anisms must be operating to result in both differential stability 
of a single mRNA species in different cell types, and regulated 
stabilities of messages within the one tissue. In the genes for 
c-fos [ 1,2] and c-myc [3] there are several determinants of rapid 
mRNA turnover, found both in coding and untranslated re- 
gions (UTRs). The most intensively studied instability elements 
are AU-rich sequences found in the 3’UTRs of genes such as 
GM-CSF [4], c-fos [l] and urokinase-type plasminogen activa- 
tor (UPA) [5]. Recent analysis of the 3’UTR of UPA mRNA has 
shown that AU-rich sequences and at least two other regions 
independently confer instability to a heterologous mRNA [5]. 
One of these regions required ongoing RNA synthesis for its 
operation as an instability element. 
UPA is a serine protease which cleaves plasminogen to yield 
plasmin, an extracellular protease of broad specificity [6]. Plas- 
min directly, or indirectly by activation of other proteases, 
catalyses the breakown of extracellular matrix allowing cell 
movement and changes in tissue architecture. The apparent 
involvement of UPA in growth and metastasis of tumours [7,8] 
has led to interest in the regulation of UPA expression. One 
study has suggested that increased metastatic potential of rat 
mammary adenocarcinoma lines could be a consequence of 
increased nuclear stability of UPA mRNA [9]. Production of 
UPA within tumours may also come from non-malignant 
stromal cells [lo], amongst which macrophages are well repre- 
sented [11,12]. 
UPA expression in macrophages may be important in migra- 
tion to sites of inflammation, and is regulated by the macro- 
phage colony stimulating factor (CSF-I), the major growth and 
differentiation factor for the mononuclear phagocyte lineage. 
In mouse bone marrow derived macrophages (BMM) uPA 
mRNA levels can increase up to 40-fold with CSF- 1 stimulation 
([13] and K. Stacey, unpublished). In this work we have studied 
the decline in UPA mRNA following CSF-1 removal, and 
shown that ongoing transcription is necessary for this decline. 
*Corresponding author. Fax: (61) (7) 365 4388. 
2. Materials and methods 
Balb/c bone marrow derived macrophages (BMM) were prepared as 
described [14], and used after 7 days differentiation in culture with lo4 
U/ml recombinant human CSF-1 (Chiron Corp.). 
Total RNA was extracted from cells [15] and run on MOPS/formal- 
dehyde denaturing gels. RNA was transferred to Hybond N nylon 
membrane (Amersham) and hybridised with 3zP-labelled DNA probes. 
Probes used were: mouse UPA cDNA; mouse c-myc cDNA; 18 S rRNA, 
a 24 bp oligonucleotide complimentary to murine 18 S rRNA (5’-CAT 
GGT AGG CAC GGC GAC TAC CAT-3’). 
3. Results and discussion 
The rate of decay of UPA mRNA after removal of CSF-1 
from BMM was examined in Fig. 1. BMM were washed with 
PBS and re-plated in medium without CSF-1 and RNA was 
harvested at various times thereafter. From Fig. 1 and another 
3 experiments (results not shown), UPA mRNA levels decreased 
after removal of CSF-1 with a half-life of approximately 2 h. 
Given that some new UPA mRNA may have been synthesised 
during this time, the real half-life of UPA mRNA in the absence 
of CSF-1 must be less than 2 h. In order to prevent new mRNA 
synthesis the cells were washed with PBS and re-plated in CSF- 
l-free medium with the RNA synthesis inhibitor DRB. Al- 
though it was expected that the rate of disappearance of mRNA 
should be greater in the presence of DRB, the inhibitor actually 
stabilised the message (Fig. l), and no decay was detected in 
a 4 h incubation. 
To determine whether the stabilisation of the UPA message 
was due to RNA synthesis inhibition or some other effect of 
DRB, two other RNA synthesis inhibitors were used. Actino- 
mycin D (Fig. 2) and a-amanitin (result not shown) both pre- 
vented decay of the mRNA. These three inhibitors have quite 
different stuctures and activities. The antibiotic actinomycin D 
can inhibit nearly all RNA synthesis [16] by intercalation in 
DNA. Actinomycin D also inhibits mRNA binding to ribo- 
somes and subsequent protein synthesis [17]. a-Amanitin is an 
octapeptide which inhibits RNA polymerase II and, to a lesser 
extent, RNA polymerase III [18]. DRB is an adenosine ana- 
logue which selectively affects RNA polymerase II-mediated 
transcription [ 191. The fact that three RNA synthesis inhibitors 
all stabilised the UPA message suggests that the stabilisation is 
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Fig. 1. Decay of UPA mRNA after removal of CSF-1, in the presence and absence of DRB. CSF-1 treated BMM were washed with PBS and re-plated 
in the absence of CSF-1, with or without 20 pg/rnl DRB. Total RNA was collected at various times thereafter and analysed by Northern blot and 
hybridisation to UPA and c-myc cDNA probes, and an oligo specific for 18 S rRNA as a loading control. 
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Fig. 2. Analysis of UPA mRNA following treatment of cells with actinomycin D. CSF-1 treated BMM were washed with PBS and replated in the 
presence or absence of CSF-1, with 5 @ml actinomycin D. Total RNA was collected at various times thereafter and analysed by Northern blot and 
hybridisation to uPA and c-myc cDNA probes, and an oligo specific for 1 8s rRNA as a loading control. 
due to RNA synthesis inhibition itself, rather than some other 
property of the inhibitors. Blots were re-probed with c-myc, 
another CSF-1 inducible gene [20]. c-myc decayed after removal 
of CSF-1 with a half-life of approximately 30 min, and this was 
not significantly affected by DRB or actinomycin D (Figs. 1 
and 2). The inhibitors are therefore not having a general effect 
on decay of CSF-l-inducible messages in macrophages. Clearly 
the rate of turnover of the message in the presence of CSF-1 
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could not be determined using RNA synthesis inhibitors. De- 
termination of whether CSF-1 affects the stability of UPA 
mRNA would require pulse chase analysis [21]. 
One explanation for stabilisation of UPA mRNA by RNA 
synthesis inhibition is that transcription is required to produce 
a factor involved in UPA mRNA degradation. Such a factor 
could be either constitutive but unstable, or induced following 
CSF-1 removal. In the first possibility, UPA mRNA would 
always be unstable, and regulation would be via changes in the 
rate of transcription. After RNA synthesis inhibition, UPA 
mRNA would initially degrade, but gradually be stabilised as 
the labile degradative factor disappeared. Since UPA mRNA 
can be stabilised early after addition of inhibitors (Figs. 1 and 
2) we favour a model where there is induction of a factor 
following removal of CSF-1. In either of these models, inhib- 
itors of protein synthesis such as cycloheximide should also 
stabilise the UPA mRNA. Cycloheximide can prevent the de- 
cline in UPA following CSF-1 removal (result not shown), but 
this effect is not interpretable because cycloheximide can itself 
induce UPA transcription in macrophages [22]. 
Stabilisation of a number of other messages by RNA synthe- 
sis inhibition has been observed. Actinomycin D, a-amanitin 
and DRB all prevented normal decline in neurofilament 
mRNA levels in cultured dorsal root ganglia [23]. Actinomycin 
D or DRB prevented the decline in follicle stimulating 
hormone-/I mRNA seen after inhibin or follistatin treatment of 
pituitary cells [24]. 
Significant stabilisation of UPA mRNA by RNA synthesis 
inhibition is not seen in all cell types. For example, a half-life 
of 70 min was observed in LLC-PK, pig kidney epithelial cells 
treated with DRB [21]. By expressing chimaeric B-globin UPA 
mRNA constructs in LLC-PK, cells, the UPA 3’UTR as a 
whole was shown to confer instability to the ,&globin message 
in the presence of RNA synthesis inhibition [5]. When the 3’ 
region was dissected, three regions causing instability were 
identified. One section apparently destabilised the /I-globin 
message, but required ongoing RNA synthesis for the instabil- 
ity to be observed. Thus it may be that this region dominates 
in the regulation of UPA mRNA stability in macrophages, 
whilst its effect is masked by other instability regions in LLC- 
PK, cells. In both c-fos[l] and c-myc [3] mRNAs, instability 
elements were found which did not operate efficiently in the 
presence of RNA synthesis inhibitors. However, in the systems 
studied, other instability elements within the same messages 
were dominant, and stabilisation by DRB or actinomycin D 
was not detected with the full-length message. 
Whilst useful information on mRNA half-life has been ob- 
tained using RNA synthesis inhibition methods, caution should 
be exercised in the interpretation of such experiments. In the 
case of macrophages, the UPA gene is inducible, so stabilisation 
of the message by DRB and actinomycin D was easily detected 
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by comparison with the normal decay curve after removal of 
CSF-1. For cell types which have constitutive expression no 
such comparison can be made. Long half-lives of 3@46 h deter- 
mined for UPA mRNA in tumour cell lines [25] really require 
confirmation with methods which do not use RNA synthesis 
inhibitors, such as pulse-chase analysis. 
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